Bioretec

0.91 EUR

+2.25 %

1,682 following

BRETEC

First North Finland

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

Compare

+2.25 %

-35.69 %

-49.58 %

-53.43 %

-60.42 %

-51.53 %

-39.87 %

-67.69 %

Bioretec operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio includes, for example, implants for pediatric and adult orthopedics and other materials for bone and soft tissue injuries. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic region.

Market cap

28.02M EUR

Turnover

5.16K EUR

P/E (adj.) (25e)

EV/EBIT (adj.) (25e)

P/B (25e)

EV/S (25e)

Dividend yield-% (25e)

Coverage

Recommendation

Accumulate

Target price

Updated

29.10.2025

Disclaimer

Antti Siltanen

Analyst

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

13.11.

2025

Business review Q3'25

Risk

Business risk

Valuation risk

Low

High

All

Research

Webcasts

Press releases

ShowingAll content types

Regulatory press release10/31/2025, 6:30 AM

Correction: Bioretec Ltd's Half-year report 2025

Bioretec

Regulatory press release10/27/2025, 7:14 PM

Inside information: Bioretec adjusts and restates previously reported net sales FOR H1/2025 and does not expect accelerated sales in 2025

Bioretec

Regulatory press release10/27/2025, 8:00 AM

Inside information: Bioretec is revising its financial targets, deems that the current financial targets will not be met and withdraws its financial targets

Bioretec

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Create account

Press release10/1/2025, 12:00 PM

Bioretec's RemeOs™ Trauma Screw Approved for Transitional Pass-Through Payment in the U.S.

Bioretec

Press release10/1/2025, 12:00 PM

Bioretec's RemeOs™ Screw LAG Solid Receives CMS Transitional Pass-Through Payment in the US

Bioretec

Regulation of medical devices and diagnostics in Europe

Analyst Comment9/19/2025, 5:18 AM by

Antti Siltanen

Regulation of medical devices and diagnostics in Europe

The EU is the world's second largest market for medical devices after the United States. In this article, we will go through the basics of EU regulation from an investor's perspective.

Bioretec Aiforia Technologies Nexstim Biohit Optomed Revenio Group Modulight Detection Technology Nightingale Health Bittium

Regulatory press release9/16/2025, 4:30 PM

Composition of Bioretec's Shareholders' Nomination Board

Bioretec

Regulatory press release9/15/2025, 2:30 PM

Inside information: Anne-Mari Matikainen appointed as Interim Chief Financial Officer of Bioretec; CFO Johanna Salko to depart before year-end

Bioretec

Regulatory press release9/15/2025, 12:15 PM

Antti Siltanen

Classification of medical devices and regulatory processes in the United States

We continue our series of articles focusing on Life Science investing, the first four parts of which focused on drug development. Subsequent articles will cover medical devices.

Bioretec Nexstim Optomed Revenio Group Modulight Bittium Detection Technology

Press release9/2/2025, 12:15 PM

Bioretec Appoints Jordy Winters as Vice President of OUS Sales to Accelerate International Growth

Bioretec

Regulatory press release8/28/2025, 7:15 AM

Bioretec Ltd: Notification in accordance with chapter 9, section 10 of the Securities Market Act on a change in holdings (W&M GmbH)

Bioretec

Press release8/27/2025, 1:00 PM

Forum discussions

Now that my own schedule has calmed down a bit, I could also comment on the latest news here. This is the first time I’ve encountered a situation where figures have to be corrected retrospectively. It also seems to be a genuinely rare situation on a general level. At the same time...

10/29/2025, 2:20 PM

by Antti Siltanen

Siltanen has published a new company report on Bioretec following the latest developments. Bioretec announced on Monday evening that the company is significantly revising its previously reported H1’25 figures downwards. At the same time, the outlook for the rest of the year was weakened...

10/29/2025, 6:07 AM

by Sijoittaja-alokas

I don’t know anything either, but could it be that US hospitals have their storerooms full of titanium screws that are used to repair a thousand different fractures, including the ankle malleolus? And they don’t bother to acquire and test a new screw that can only be used for the...

10/31/2025, 11:37 AM

This is certainly true at the moment. But I would think that in the longer term, if/when there is more clinical evidence and experience with Bioretec’s products, there will also be pressure in the US to start using them. If there is a product on the market that reduces the patient...

10/31/2025, 11:05 AM

Regarding the discussion above, I tasked Gemini with it as I didn’t feel like writing myself. Gemini handled the task well. ““““““““““““ Yes, US insurance companies have significant influence over what products and treatments healthcare providers use. This influence stems from the...

10/31/2025, 3:13 PM

by j.sälli

Thanks for the notice, it wasn’t intentional, it’s now open…

10/31/2025, 7:28 AM

by Antti Siltanen

The whole company is quite a joke and a farce, I wonder if new figures will be drawn again next week… Otherwise, one could even laugh at the situation, but these mistakes made by the company will be costly for investors, at least for some…

10/31/2025, 7:24 AM

by Timo Heikkerö

Bioretec

0.91 EUR

+2.25 %

Coverage

Revenue and EBIT-%

EPS and dividend

Financial calendar

Risk

Correction: Bioretec Ltd's Half-year report 2025

Inside information: Bioretec adjusts and restates previously reported net sales FOR H1/2025 and does not expect accelerated sales in 2025

Inside information: Bioretec is revising its financial targets, deems that the current financial targets will not be met and withdraws its financial targets

Join Inderes community

FREE account

PREMIUM account

Bioretec's RemeOs™ Trauma Screw Approved for Transitional Pass-Through Payment in the U.S.

Bioretec's RemeOs™ Screw LAG Solid Receives CMS Transitional Pass-Through Payment in the US

Regulation of medical devices and diagnostics in Europe

Composition of Bioretec's Shareholders' Nomination Board

Inside information: Anne-Mari Matikainen appointed as Interim Chief Financial Officer of Bioretec; CFO Johanna Salko to depart before year-end

New shares of Bioretec Ltd subscribed with option rights have been registered with the trade register

Inside information: Bioretec updates the commercialization status of RemeOs™ DrillPin

Bioretec Appoints Dr. Christopher W. DiGiovanni to Scientific Advisory Board

Classification of medical devices and regulatory processes in the United States

Bioretec Appoints Jordy Winters as Vice President of OUS Sales to Accelerate International Growth

Bioretec Ltd: Notification in accordance with chapter 9, section 10 of the Securities Market Act on a change in holdings (W&M GmbH)

Bioretec Appoints Sarah van Hellenberg Hubar-Fisher as Chief Executive Officer

Inside information: Bioretec Appoints Sarah van Hellenberg Hubar-Fisher as Chief Executive Officer

Bioretec Ltd's Half-year report 2025: Strong support for future growth from a successful rights issue

René Eve appointed as Director of Operations of Bioretec Ltd.

Bioretec Ltd adjusts the terms and conditions of its stock option programs due to the completed rights issue

New shares of Bioretec Ltd registered with the trade register

Forum discussions